Trial · NCT00733343
Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure
NCT00733343, Not applicable, Completed, ResMed; results first posted 2020-05-12
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure. Trials, record NCT00733343. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00733343
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure
- NCT number
- NCT00733343
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 1,325 participants, actual
- Lead sponsor
- ResMed
- Conditions
- Heart Failure, Sleep Disordered Breathing
- Interventions
- Europe: AutoSet CS (USA: VPAP Adapt SV)
- First posted
- 2008-08-13
- Last updated
- 2020-05-12
- Other registries' IDs
- isrctn:ISRCTN19572887
- Results first posted
- 2020-05-12
Source ClinicalTrials.gov
Registered outcomes42
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | All Cause Mortality or Unplanned Hospitalisation/Prolongation of Hospitalisation for Worsening Heart Failure | time to first event, assessed for up to 70 weeks | |
| Primary | Cardiovascular Mortality or Unplanned Hospitalisation/Prolongation of Hospitalisation for Worsening Heart Failure | time to first event, assessed for up to 70 weeks | |
| Primary | All Cause Mortality or All Cause Unplanned Hospitalisation/Prolongation of Hospitalisation | time to first event, assessed for up to 70 weeks | |
| Secondary | Death From Any Cause | the last follow up or at the last available observation within Follow Up (FU), assessed for up to 70 weeks | |
| Secondary | Non-cardiovascular Death | the last follow up or at the last available observation within FU, assessed for up to 70 weeks | |
| Secondary | Cardiovascular Death | the last follow up or at the last available observation within FU, assessed for up to 70 weeks | |
| Secondary | Unplanned Hospitalisation/Prolongation of Hospitalisation Due to Worsening of Heart Failure | the last follow up or at the last available observation within FU, assessed for up to 70 weeks | |
| Secondary | Unplanned Hospitalisation/Prolongation of Hospitalisation for Other Reasons or Death | the last follow up or at the last available observation within FU, assessed for up to 70 weeks | |
| Secondary | Adequate Shock in Patients With ICD (Evaluation of Appropriateness Will Also be Made by the Endpoint Review Committee, ERC), Long-Term Atrial Defibrillator Insertion or Cardiovascular Death | the last follow up or at the last available observation within FU, assessed for up to 70 weeks | |
| Secondary | First Survived Resuscitation for Any Reason (Evaluation Will Also be Made by the ERC) | the last follow up or at the last available observation within FU, assessed for up to 70 weeks |
1 to 10 of 42Source ClinicalTrials.gov
See all 42 registered outcomesOutcomes42
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | All Cause Mortality or Unplanned Hospitalisation/Prolongation of Hospitalisation for Worsening Heart Failure | time to first event, assessed for up to 70 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Cardiovascular Mortality or Unplanned Hospitalisation/Prolongation of Hospitalisation for Worsening Heart Failure | time to first event, assessed for up to 70 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | All Cause Mortality or All Cause Unplanned Hospitalisation/Prolongation of Hospitalisation | time to first event, assessed for up to 70 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Death From Any Cause | the last follow up or at the last available observation within Follow Up (FU), assessed for up to 70 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Non-cardiovascular Death | the last follow up or at the last available observation within FU, assessed for up to 70 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Cardiovascular Death | the last follow up or at the last available observation within FU, assessed for up to 70 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Unplanned Hospitalisation/Prolongation of Hospitalisation Due to Worsening of Heart Failure | the last follow up or at the last available observation within FU, assessed for up to 70 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Unplanned Hospitalisation/Prolongation of Hospitalisation for Other Reasons or Death | the last follow up or at the last available observation within FU, assessed for up to 70 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Adequate Shock in Patients With ICD (Evaluation of Appropriateness Will Also be Made by the Endpoint Review Committee, ERC), Long-Term Atrial Defibrillator Insertion or Cardiovascular Death | the last follow up or at the last available observation within FU, assessed for up to 70 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | First Survived Resuscitation for Any Reason (Evaluation Will Also be Made by the ERC) | the last follow up or at the last available observation within FU, assessed for up to 70 weeks | Participants | COUNT_OF_PARTICIPANTS |
1 to 10 of 42Source ClinicalTrials.gov
See all 42 outcomesResults by group56
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| All Cause Mortality or Unplanned Hospitalisation/Prolongation of Hospitalisation for Worsening Heart Failure | Treatment Group | 360 | Participants | ||
| All Cause Mortality or Unplanned Hospitalisation/Prolongation of Hospitalisation for Worsening Heart Failure | Control Group | 335 | Participants | ||
| Cardiovascular Mortality or Unplanned Hospitalisation/Prolongation of Hospitalisation for Worsening Heart Failure | Treatment Group | 345 | Participants | ||
| Cardiovascular Mortality or Unplanned Hospitalisation/Prolongation of Hospitalisation for Worsening Heart Failure | Control Group | 317 | Participants | ||
| All Cause Mortality or All Cause Unplanned Hospitalisation/Prolongation of Hospitalisation | Treatment Group | 482 | Participants | ||
| All Cause Mortality or All Cause Unplanned Hospitalisation/Prolongation of Hospitalisation | Control Group | 465 | Participants | ||
| Death From Any Cause | Treatment Group | 232 | Participants | ||
| Death From Any Cause | Control Group | 193 | Participants | ||
| Non-cardiovascular Death | Treatment Group | 33 | Participants | ||
| Non-cardiovascular Death | Control Group | 35 | Participants |
1 to 10 of 56Source ClinicalTrials.gov
See all 56 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Treatment Group | 666 | |
| Overall Study | STARTED | Control Group | 659 | |
| Overall Study | COMPLETED | Treatment Group | 583 | |
| Overall Study | COMPLETED | Control Group | 578 | |
| Overall Study | NOT COMPLETED | Treatment Group | 83 | |
| Overall Study | NOT COMPLETED | Control Group | 81 |
Source ClinicalTrials.gov
Adverse events24
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Cardiovascular death | Cardiac disorders | Treatment Group | 199 | 666 | 199 |
| serious | Cardiovascular death | Cardiac disorders | Control Group | 158 | 659 | 158 |
| serious | Primary end point | General disorders | Treatment Group | 360 | 666 | 360 |
| serious | Primary end point | General disorders | Control Group | 335 | 659 | 335 |
| serious | Firt secondary endpoint | Cardiac disorders | Treatment Group | 345 | 666 | 345 |
| serious | Firt secondary endpoint | Cardiac disorders | Control Group | 317 | 659 | 317 |
| serious | Second secondary endpoint | General disorders | Treatment Group | 482 | 666 | 482 |
| serious | Second secondary endpoint | General disorders | Control Group | 465 | 659 | 465 |
| serious | Hospitalization for any cause | General disorders | Treatment Group | 452 | 666 | 452 |
| serious | Hospitalization for any cause | General disorders | Control Group | 448 | 659 | 448 |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment Group | 232 | 666 |
| Total, all-cause mortality | Control Group | 193 | 659 |
| Total, other adverse events | Treatment Group | 0 | 666 |
| Total, other adverse events | Control Group | 0 | 659 |
| Total, serious adverse events | Treatment Group | 482 | 666 |
| Total, serious adverse events | Control Group | 465 | 659 |
Source ClinicalTrials.gov
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons13
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Treatment Group vs Control Group: First Survived Resuscitation of Sudden Cardiac Arrest (Evaluation Will Also be Made by the ERC) | Trial comparisons |
| Treatment Group vs Control Group: Unplanned Hospitalisation/Prolongation of Hospitalisation for Other Reasons or Death | Trial comparisons |
| Treatment Group vs Control Group: Cardiovascular Mortality or Unplanned Hospitalisation/Prolongation of Hospitalisation for Worsening Heart Failure | Trial comparisons |
| Treatment Group vs Control Group: First Survived Resuscitation for Any Reason (Evaluation Will Also be Made by the ERC) | Trial comparisons |
| Treatment Group vs Control Group: Non-cardiovascular Death | Trial comparisons |
| Treatment Group vs Control Group: All Cause Mortality or All Cause Unplanned Hospitalisation/Prolongation of Hospitalisation | Trial comparisons |
| Treatment Group vs Control Group: Unplanned Hospitalisation/Prolongation of Hospitalisation Due to Worsening of Heart Failure | Trial comparisons |
| Treatment Group vs Control Group: Death From Any Cause | Trial comparisons |
| Treatment Group vs Control Group: All Cause Mortality or Unplanned Hospitalisation/Prolongation of Hospitalisation for Worsening Heart Failure | Trial comparisons |
| Treatment Group vs Control Group: deaths from any cause | Trial comparisons |
1 to 10 of 13
See all 13 trial comparisonsTests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00733343
GET https://conductscience.org/api/trials/v1/NCT00733343/registered?page=2